Cargando…

Implications of Seizure-Cluster Treatment on Healthcare Utilization: Use of Approved Rescue Medications

PURPOSE: People with epilepsy may experience seizure clusters despite a stable regimen of antiseizure medications. Such clusters have the potential to last ≥24 hours, typically occur in the community setting, and may progress to medical emergencies, such as status epilepticus, if untreated. Thus, lo...

Descripción completa

Detalles Bibliográficos
Autores principales: Rabinowicz, Adrian L, Faught, Edward, Cook, David F, Carrazana, Enrique
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9619205/
https://www.ncbi.nlm.nih.gov/pubmed/36325434
http://dx.doi.org/10.2147/NDT.S376104
_version_ 1784821224343339008
author Rabinowicz, Adrian L
Faught, Edward
Cook, David F
Carrazana, Enrique
author_facet Rabinowicz, Adrian L
Faught, Edward
Cook, David F
Carrazana, Enrique
author_sort Rabinowicz, Adrian L
collection PubMed
description PURPOSE: People with epilepsy may experience seizure clusters despite a stable regimen of antiseizure medications. Such clusters have the potential to last ≥24 hours, typically occur in the community setting, and may progress to medical emergencies, such as status epilepticus, if untreated. Thus, long-acting rescue therapy for seizure clusters is needed that can be administered by nonmedical individuals outside a hospital. Benzodiazepines are the foundation of rescue therapy for seizure clusters. The approved outpatient treatments (ie, diazepam, midazolam) have differing profiles that may affect multiple aspects of health-care utilization. The current labeling of these medications allows for a second dose if needed to control the cluster. Although no head-to-head studies directly comparing rescue treatments have been conducted, differences between studies with generally similar designs may provide context for the potential importance of second doses of rescue therapy on health-care utilization. METHODS: For this analysis, large, long-term, open-label studies of approved seizure-cluster treatments designed for use by nonmedical caregivers were reviewed, and the percentage of seizure clusters for which a second dose was used or that were not controlled at 6, 12, and 24 hours was examined. Available data on hospitalizations were also collected. RESULTS: The 3 identified studies meeting the inclusion criteria were for use of diazepam rectal gel, intranasal midazolam, and diazepam nasal spray. Across these studies, the use of a second dose ranged from <40% at 6 hours to <13% at 24 hours. Hospitalizations and serious treatment-emergent adverse events were reported variably across these studies. CONCLUSION: These results demonstrate the importance of second doses of rescue therapy for seizure clusters for optimizing health-care utilization. Need for second doses should be included as one component. In turn, when second doses are needed, they have the potential to curtail emergency department use and hospitalization and to prevent further seizure clusters.
format Online
Article
Text
id pubmed-9619205
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-96192052022-11-01 Implications of Seizure-Cluster Treatment on Healthcare Utilization: Use of Approved Rescue Medications Rabinowicz, Adrian L Faught, Edward Cook, David F Carrazana, Enrique Neuropsychiatr Dis Treat Review PURPOSE: People with epilepsy may experience seizure clusters despite a stable regimen of antiseizure medications. Such clusters have the potential to last ≥24 hours, typically occur in the community setting, and may progress to medical emergencies, such as status epilepticus, if untreated. Thus, long-acting rescue therapy for seizure clusters is needed that can be administered by nonmedical individuals outside a hospital. Benzodiazepines are the foundation of rescue therapy for seizure clusters. The approved outpatient treatments (ie, diazepam, midazolam) have differing profiles that may affect multiple aspects of health-care utilization. The current labeling of these medications allows for a second dose if needed to control the cluster. Although no head-to-head studies directly comparing rescue treatments have been conducted, differences between studies with generally similar designs may provide context for the potential importance of second doses of rescue therapy on health-care utilization. METHODS: For this analysis, large, long-term, open-label studies of approved seizure-cluster treatments designed for use by nonmedical caregivers were reviewed, and the percentage of seizure clusters for which a second dose was used or that were not controlled at 6, 12, and 24 hours was examined. Available data on hospitalizations were also collected. RESULTS: The 3 identified studies meeting the inclusion criteria were for use of diazepam rectal gel, intranasal midazolam, and diazepam nasal spray. Across these studies, the use of a second dose ranged from <40% at 6 hours to <13% at 24 hours. Hospitalizations and serious treatment-emergent adverse events were reported variably across these studies. CONCLUSION: These results demonstrate the importance of second doses of rescue therapy for seizure clusters for optimizing health-care utilization. Need for second doses should be included as one component. In turn, when second doses are needed, they have the potential to curtail emergency department use and hospitalization and to prevent further seizure clusters. Dove 2022-10-25 /pmc/articles/PMC9619205/ /pubmed/36325434 http://dx.doi.org/10.2147/NDT.S376104 Text en © 2022 Rabinowicz et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Review
Rabinowicz, Adrian L
Faught, Edward
Cook, David F
Carrazana, Enrique
Implications of Seizure-Cluster Treatment on Healthcare Utilization: Use of Approved Rescue Medications
title Implications of Seizure-Cluster Treatment on Healthcare Utilization: Use of Approved Rescue Medications
title_full Implications of Seizure-Cluster Treatment on Healthcare Utilization: Use of Approved Rescue Medications
title_fullStr Implications of Seizure-Cluster Treatment on Healthcare Utilization: Use of Approved Rescue Medications
title_full_unstemmed Implications of Seizure-Cluster Treatment on Healthcare Utilization: Use of Approved Rescue Medications
title_short Implications of Seizure-Cluster Treatment on Healthcare Utilization: Use of Approved Rescue Medications
title_sort implications of seizure-cluster treatment on healthcare utilization: use of approved rescue medications
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9619205/
https://www.ncbi.nlm.nih.gov/pubmed/36325434
http://dx.doi.org/10.2147/NDT.S376104
work_keys_str_mv AT rabinowiczadrianl implicationsofseizureclustertreatmentonhealthcareutilizationuseofapprovedrescuemedications
AT faughtedward implicationsofseizureclustertreatmentonhealthcareutilizationuseofapprovedrescuemedications
AT cookdavidf implicationsofseizureclustertreatmentonhealthcareutilizationuseofapprovedrescuemedications
AT carrazanaenrique implicationsofseizureclustertreatmentonhealthcareutilizationuseofapprovedrescuemedications